Announcement PDF Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.. Amended 01/01/11 Name of Entity: Alterity Therapeutics Limited ABN: 37 080 699 065 (ASX:ATH) We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director: Mr. Brian Meltzer Date of Last Notice: 11 January 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct and indirect Nature of indirect interest (including registered holder) Related entity Date of change 31 August 2024 Note: Provide details of the circumstances giving rise to the relevant interest. No. of securities held prior to change Class Shares 7,142,857 326,666 7,469,523 Options 16,523,809 16,523,809 Direct Shares - Options - Indirect - - - - Shares - Options 7,142,857 7,142,857 Direct Indirect Total Unlisted Options Number acquired Total Number disposed Direct Indirect Total + See chapter 19 for defined terms. 11/3/2002 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back n/a Shares Options Direct 7,142,857 9,380,952 Indirect 326,666 Total 7,469,523 9,380,952 Expiry of options without exercise or conversion Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 - +Closed Period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided on what date was this provided? No N/A N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name of Entity: Alterity Therapeutics Limited ABN: 37 080 699 065 (ASX:ATH) We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director: Mr. Peter Marks Date of Last Notice: 11 January 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct and indirect Nature of indirect interest (including registered holder) Related entity Date of change 31 August 2024 Note: Provide details of the circumstances giving rise to the relevant interest. No. of securities held prior to change Class Shares 7,185,986 7,185,968 Options 7,000,000 9,523,809 16,523,809 Direct Shares - Options - Indirect - - - - Shares - Options 7,142,857 7,142,857 Direct Indirect Total Unlisted Options Number acquired Total Number disposed Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Direct Indirect Total n/a + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Appendix 3Y Change of Director’s Interest Notice No. of securities held after change Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Shares Options Direct 7,000,000 Indirect 7,185,986 2,380,952 Total 7,185,968 9,380,952 Expiry of unlisted options without exercise or conversion Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change Part 3 - +Closed Period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade to proceed during this period? If prior written clearance was provided on what date was this provided? No N/A N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011